Literature DB >> 10605747

Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.

U Hedner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10605747

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  8 in total

Review 1.  Recombinant factor VIIa: a review on its clinical use.

Authors:  Massimo Franchini
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

2.  Successful use of recombinant factor VIIa for hemostasis during total knee replacement in a severe hemophiliac with high-titer factor VIII inhibitor.

Authors:  Marcus E Carr; Thomas P Loughran; John A Cardea; Wade K Smith; Jan G Kuhn; Maribeth V Dottore
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

Review 3.  Dose titration of recombinant factor VIIa using thromboelastograph monitoring in a child with hemophilia and high titer inhibitors to factor VIII: a case report and brief review.

Authors:  Cody C Trowbridge; Alfred H Stammers; Nancy Ciccarelli; Myra Klayman
Journal:  J Extra Corpor Technol       Date:  2006-09

Review 4.  Successful perioperative management of factor X deficiency associated with primary amyloidosis.

Authors:  Kazuaki Takabe; Peter R Holman; Kenneth D Herbst; Catherine A Glass; Michael Bouvet
Journal:  J Gastrointest Surg       Date:  2004 Mar-Apr       Impact factor: 3.452

5.  Recombinant Activated Factor VII Significantly Reduces Transfusion Requirements in Cardiothoracic Surgery.

Authors:  Hesham R Omar; Garrett Enten; Rachel Karlnoski; Yiu-Hei Ching; Devanand Mangar; Enrico M Camporesi
Journal:  Drugs R D       Date:  2015-06

6.  Recombinant Factor VIIa Reduces Bleeding after Blunt Liver Injury in a Pig Model of Dilutional Coagulopathy under Severe Hypothermia.

Authors:  Henri M H Spronk; Till Braunschweig; Rolf Rossaint; Dirk C Wüst; Rene van Oerle; Brian Lauritzen; Rene Tolba; Oliver Grottke
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

Review 7.  Recombinant factor VIIa for uncontrollable bleeding in patients with extracorporeal membrane oxygenation: report on 15 cases and literature review.

Authors:  Xavier Repessé; Siu Ming Au; Nicolas Bréchot; Jean-Louis Trouillet; Pascal Leprince; Jean Chastre; Alain Combes; Charles-Edouard Luyt
Journal:  Crit Care       Date:  2013-03-25       Impact factor: 9.097

8.  Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model.

Authors:  Oliver Grottke; Joanne van Ryn; Henri M H Spronk; Rolf Rossaint
Journal:  Crit Care       Date:  2014-02-05       Impact factor: 9.097
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.